BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Farolfi A, Petrone M, Scarpi E, Gallà V, Greco F, Casanova C, Longo L, Cormio G, Orditura M, Bologna A, Zavallone L, Ventriglia J, Franzese E, Loizzi V, Giardina D, Pigozzi E, Cioffi R, Pignata S, Giorda G, De Giorgi U. Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24). Target Oncol 2018;13:469-79. [PMID: 29948780 DOI: 10.1007/s11523-018-0574-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Gurioli G, Tedaldi G, Farolfi A, Petracci E, Casanova C, Comerci G, Danesi R, Arcangeli V, Ravegnani M, Calistri D, Zampiga V, Cangini I, Fonzi E, Virga A, Tassinari D, Rosati M, Ulivi P, De Giorgi U. Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients. Int J Mol Sci 2022;23. [PMID: 36555431 DOI: 10.3390/ijms232415789] [Reference Citation Analysis]
2 Bizzarri N, D’indinosante M, Marchetti C, Tudisco R, Turchiano F, Scambia G, Fagotti A. The prognostic role of systemic inflammatory markers in apparent early-stage ovarian cancer. Int J Clin Oncol 2022. [DOI: 10.1007/s10147-022-02272-z] [Reference Citation Analysis]
3 Wang H, Zhang JR, Chen S, Hou P, Chen QF, Weng ZQ, Shang-Guan XC, Lin BQ, Chen XQ. Who would avoid severe adverse events from nasointestinal tube in small bowel obstruction? A matched case-control study. BMC Gastroenterol 2022;22:332. [PMID: 35799135 DOI: 10.1186/s12876-022-02405-8] [Reference Citation Analysis]
4 El Bairi K, Al Jarroudi O, Afqir S. Inexpensive Systemic Inflammatory Biomarkers in Ovarian Cancer: An Umbrella Systematic Review of 17 Prognostic Meta-Analyses. Front Oncol 2021;11:694821. [PMID: 34631526 DOI: 10.3389/fonc.2021.694821] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Svaton M, Blazek J, Krakorova G, Buresova M, Teufelova Z, Vodicka J, Hurdalkova K, Barinova M, Pesek M. Laboratory Parameters are Possible Prognostic Markers in Patients with Advanced-stage NSCLC Treated with Bevacizumab plus Chemotherapy. J Cancer 2021;12:5753-9. [PMID: 34475989 DOI: 10.7150/jca.58851] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Nakanishi K, Yamada T, Ishikawa G, Suzuki S. Beyond BRCA Status: Clinical Biomarkers May Predict Therapeutic Effects of Olaparib in Platinum-Sensitive Ovarian Cancer Recurrence. Front Oncol 2021;11:697952. [PMID: 34395265 DOI: 10.3389/fonc.2021.697952] [Reference Citation Analysis]
7 Marchetti C, D'Indinosante M, Bottoni C, Di Ilio C, Di Berardino S, Costantini B, Minucci A, Vertechy L, Scambia G, Fagotti A. NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer. Sci Rep 2021;11:11125. [PMID: 34045513 DOI: 10.1038/s41598-021-90361-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
8 Ciocan A, Ciocan RA, Al Hajjar N, Gherman CD, Bolboacă SD. Abilities of Pre-Treatment Inflammation Ratios as Classification or Prediction Models for Patients with Colorectal Cancer. Diagnostics (Basel) 2021;11:566. [PMID: 33801031 DOI: 10.3390/diagnostics11030566] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Farolfi A, Scarpi E, Greco F, Bergamini A, Longo L, Pignata S, Casanova C, Cormio G, Bologna A, Orditura M, Zavallone L, Attademo L, Gallà V, Franzese E, Pigozzi E, Loizzi V, Giorda G, Giardina D, Cioffi R, De Giorgi U. Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study. Sci Rep 2020;10:18190. [PMID: 33097745 DOI: 10.1038/s41598-020-75316-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
10 Liu J, Li S, Zhang S, Yang C, Zhang L, Zhang B, Cheng Y, Wang C. Pretreatment prognostic nutritional index is a prognostic marker for extensive-stage small cell lung cancer patients treated with anlotinib. J Thorac Dis 2020;12:5765-73. [PMID: 33209408 DOI: 10.21037/jtd-20-755] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
11 Cao Y, Ke S, Gu J, Mao F, Yao S, Deng S, Yan L, Wu K, Liu L, Cai K. The Value of Haematological Parameters and Tumour Markers in the Prediction of Intestinal Obstruction in 1474 Chinese Colorectal Cancer Patients. Dis Markers 2020;2020:8860328. [PMID: 32855747 DOI: 10.1155/2020/8860328] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
12 Ji Y, Wang H. Prognostic prediction of systemic immune-inflammation index for patients with gynecological and breast cancers: a meta-analysis. World J Surg Oncol 2020;18:197. [PMID: 32767977 DOI: 10.1186/s12957-020-01974-w] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 9.0] [Reference Citation Analysis]
13 Baci D, Bosi A, Gallazzi M, Rizzi M, Noonan DM, Poggi A, Bruno A, Mortara L. The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors. Int J Mol Sci 2020;21:E3125. [PMID: 32354198 DOI: 10.3390/ijms21093125] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 13.3] [Reference Citation Analysis]
14 Casadei C, Lolli C, Farolfi A. Immune-checkpoint inhibitors and the importance of concomitant medications: focus on antibiotics. Ann Transl Med 2019;7:S339. [PMID: 32016057 DOI: 10.21037/atm.2019.09.99] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
15 Li X, Hu P, Liu J, Zhang J, Liu Q. Systemic immune-inflammation index predicted overall survival and radiosensitivity in advanced non-small-cell lung cancer. Future Oncol 2020;16:103-15. [PMID: 31933380 DOI: 10.2217/fon-2019-0761] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
16 Tewari KS, Monk BJ, Burger RA. Reply to Farolfi et al and Haines et al. JCO 2020;38:173-174. [DOI: 10.1200/jco.19.02334] [Reference Citation Analysis]
17 Khokhlova SV. Primary ovarian cancer: possibilities for improving treatment outcomes. Medicinskij sovet 2019. [DOI: 10.21518/2079-701x-2019-19-150-156] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Brighi N, Farolfi A, Conteduca V, Gurioli G, Gargiulo S, Gallà V, Schepisi G, Lolli C, Casadei C, De Giorgi U. The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment. Cancers (Basel) 2019;11:E1935. [PMID: 31817109 DOI: 10.3390/cancers11121935] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
19 Farolfi A, Lorusso D, Pignata S, De Giorgi U. Bevacizumab As Maintenance Treatment in Patients With Ovarian Cancer: Wait for BRCA Testing. J Clin Oncol 2020;38:172-3. [PMID: 31697587 DOI: 10.1200/JCO.19.02055] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
20 Schepisi G, Brighi N, Cursano MC, Gurioli G, Ravaglia G, Altavilla A, Burgio SL, Testoni S, Menna C, Farolfi A, Casadei C, Tonini G, Santini D, De Giorgi U. Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors. J Oncol 2019;2019:7317964. [PMID: 31641355 DOI: 10.1155/2019/7317964] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
21 Chen XQ, Xue CR, Hou P, Lin BQ, Zhang JR. Lymphocyte-to-monocyte ratio effectively predicts survival outcome of patients with obstructive colorectal cancer. World J Gastroenterol 2019; 25(33): 4970-4984 [PMID: 31543687 DOI: 10.3748/wjg.v25.i33.4970] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
22 Jiang S, Liu J, Chen X, Zheng X, Ruan J, Ye A, Zhang S, Zhang L, Kuang Z, Liu R. Platelet-lymphocyte ratio as a potential prognostic factor in gynecologic cancers: a meta-analysis. Arch Gynecol Obstet 2019;300:829-39. [PMID: 31385023 DOI: 10.1007/s00404-019-05257-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
23 Farolfi A, Gurioli G, Fugazzola P, Burgio SL, Casanova C, Ravaglia G, Altavilla A, Costantini M, Amadori A, Framarini M, Ansaloni L, De Giorgi U. Immune System and DNA Repair Defects in Ovarian Cancer: Implications for Locoregional Approaches. Int J Mol Sci 2019;20:E2569. [PMID: 31130614 DOI: 10.3390/ijms20102569] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
24 Marchetti C, Muzii L, Romito A, Benedetti Panici P. First-line treatment of women with advanced ovarian cancer: focus on bevacizumab. Onco Targets Ther 2019;12:1095-103. [PMID: 30799939 DOI: 10.2147/OTT.S155425] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
25 Murthy P, Ekeke CN, Russell KL, Butler SC, Wang Y, Luketich JD, Soloff AC, Dhupar R, Lotze MT. Making cold malignant pleural effusions hot: driving novel immunotherapies. Oncoimmunology 2019;8:e1554969. [PMID: 30906651 DOI: 10.1080/2162402X.2018.1554969] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
26 Nie D, Gong H, Mao X, Li Z. Systemic immune-inflammation index predicts prognosis in patients with epithelial ovarian cancer: A retrospective study. Gynecol Oncol 2019;152:259-64. [PMID: 30558974 DOI: 10.1016/j.ygyno.2018.11.034] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
27 Shi H, Jiang Y, Cao H, Zhu H, Chen B, Ji W. Nomogram Based on Systemic Immune-Inflammation Index to Predict Overall Survival in Gastric Cancer Patients. Dis Markers 2018;2018:1787424. [PMID: 30627220 DOI: 10.1155/2018/1787424] [Cited by in Crossref: 27] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]